Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
"When the medical system doesn't know exactly what the best recommendation is people are smart
The two main genes that produce the enzymes that break down histamine are DAO and HNMT ( 2)
As research continues to evolve, GLP-1 medications may become an integral part of more personalized and effective weight management strategies
Post-ischemic leakiness of the blood-brain barrier: a quantitative and systematic assessment by Patlak plots
Khi melanin sn sinh qu mc c th dn ti tnh trng da xn mu, nm, tn nhang